NAMENDA XR® Dosing Information

Dosing For Patients Currently Taking NAMENDA

NAMENDA XR capsules offer convenient once-daily dosing for your patients

  • Once-daily formulation aligns with once-daily AChEI regimens1
  • Can be administered day or night, with or without food2

Patients taking combination therapy with a once-daily AChEI may be able to receive all Alzheimer's disease treatments just once a day.


No titration required for patients already taking NAMENDA® (memantine HCI)

  • Patients can switch directly from the 20 mg dose (10 mg tablets twice daily) immediate-release NAMENDA to 28 mg once-daily NAMENDA XR capsules following the last dose of a 10 mg tablet. There is no study addressing the comparative efficacy of these 2 regimens2

dosing-current-patients

Note: Actual size of pills is smaller than shown.

  • In patients with severe renal impairment, it is recommended that a patient who is on NAMENDA 5 mg twice-daily tablets be switched to a NAMENDA XR 14 mg once-daily capsule following the last dose of 5 mg NAMENDA tablets2

Flexible administration

  • NAMENDA XR may be administered day or night, with or without food2
  • NAMENDA XR capsules may be opened, and the contents sprinkled on applesauce for patients who have difficulty swallowing pills2
    • Entire contents of NAMENDA XR capsules must be consumed; the dose should not be divided


Dosage and Administration

  • The recommended starting dose of NAMENDA XR is 7 mg once daily. The recommended target dose is 28 mg once daily. The dose should be increased in 7 mg increments to 28 mg once daily. The minimum recommended interval between dose increases is one week, and only if the previous dose has been well tolerated. The maximum recommended dose is 28 mg once daily.
  • It is recommended that a patient who is on a regimen of 10 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 28 mg once-daily capsules the day following the last dose of a 10 mg NAMENDA tablet. There is no study addressing the comparative efficacy of these 2 regimens.
  • It is recommended that a patient with severe renal impairment who is on a regimen of 5 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 14 mg once-daily capsules the day following the last dose of a 5 mg NAMENDA tablet.

Special Populations

  • NAMENDA XR should be administered with caution to patients with severe hepatic impairment.
  • A target dose of 14 mg/day is recommended in patients with severe renal impairment (creatinine clearance of 5-29 mL/min, based on the Cockcroft-Gault equation).

Learn how NAMENDA XR works in combination with an AChEI

View NAMENDA XR side effects and pharmacokinetic drug interactions

References:

  1. Data on file. Forest Laboratories, LLC
  2. NAMENDA XR (memantine HCl) extended-release Prescribing Information. Cincinnati, OH: Forest Pharmaceuticals, Inc.; 2014.

NAMENDA XR® (memantine hydrochloride) extended-release capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.

Important Safety Information

Contraindications

  • NAMENDA XR is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.

Warnings and Precautions

  • Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine.

Adverse Reactions

  • The most commonly observed adverse reactions in patients administered NAMENDA XR (28 mg/day) in a controlled clinical trial, defined as those occurring at a frequency of at least 5% in the NAMENDA XR group and at a higher frequency than placebo were headache (6% vs 5%), diarrhea (5% vs 4%), and dizziness (5% vs 1%).
  • NAMENDA XR has not been systematically evaluated in patients with a seizure disorder.

Drug Interactions

  • Alterations of urine pH toward the alkaline condition may lead to an accumulation of memantine with a possible increase in adverse reactions. NAMENDA XR should be used with caution under conditions that may be associated with increased urine pH including alterations by diet, drugs, and the clinical state of the patient.
  • No drug-drug interaction studies have been conducted with NAMENDA XR, specifically. The combined use of NAMENDA XR with other NMDA antagonists (amantadine, ketamine, or dextromethorphan) has not been systematically evaluated and such use should be approached with caution.

Dosage and Administration

  • The recommended starting dose of NAMENDA XR is 7 mg once daily. The recommended target dose is 28 mg once daily. The dose should be increased in 7 mg increments to 28 mg once daily. The minimum recommended interval between dose increases is one week, and only if the previous dose has been well tolerated. The maximum recommended dose is 28 mg once daily.
  • It is recommended that a patient who is on a regimen of 10 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 28 mg once-daily capsules the day following the last dose of a 10 mg NAMENDA tablet. There is no study addressing the comparative efficacy of these 2 regimens.
  • It is recommended that a patient with severe renal impairment who is on a regimen of 5 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 14 mg once-daily capsules the day following the last dose of a 5 mg NAMENDA tablet.

Special Populations

  • NAMENDA XR should be administered with caution to patients with severe hepatic impairment.
  • A target dose of 14 mg/day is recommended in patients with severe renal impairment (creatinine clearance of 5-29 mL/min, based on the Cockcroft-Gault equation).